Brainomix Receives £633,553 Funding
News Aug 25, 2015
Brainomix Limited has been awarded £633,553 by the Biomedical Catalyst (BMC), a joint programme run by the Medical Research Council (MRC) and Innovate UK. The funding is for two years and will support the development and validation of clinical decision-making support software designed to identify stroke patients who can benefit from mechanical reopening of a brain artery.
“We are very honoured to receive this award. We are now able to develop software that will empower physicians to identify stroke patients who benefit from the life-saving, but expensive treatment of mechanical clot removal,” said Dr Michalis Papadakis, Brainomix Chief Executive Officer.
The technology, called perfusion-ASPECTS, will automate the procedure to measure tissue at risk on brain CT scans and identify patients who can benefit from mechanical reopening of a brain artery. Worldwide, annually, 13,000,000 people suffer a stroke.
Recent studies show that mechanical clot removal improves patient outcome and the procedure is currently transforming stroke treatment. Patient selection is crucial for the adoption of this procedure because it costs up to £23,000 per patient.
Brainomix will build on its e-ASPECTS stroke damage measurement software to develop and validate perfusion-ASPECTS. The international reputation of the Brainomix founders in stroke will aid the successful development and clinical adoption of perfusion-ASPECTS.
Computer scientists at Carnegie Mellon University say neural networks and supervised machine learning techniques can efficiently characterize cells that have been studied using single cell RNA-sequencing (scRNA-seq). This finding could help researchers identify new cell subtypes and differentiate between healthy and diseased cells.